During solvent-evaporation encapsulation of water-soluble peptide salts, R 207 S is dissolved in dichloromethane to a concentration of 18% w/w and the active phase is emulsified into an aqueous continuous phase containing poly(vinyl alcohol) at 0.5% w/v. The polymer phase is injected through a 316L stainless steel nozzle into a 20 L jacketed vessel while a Silverson L5M-A rotor-stator mixer operates with a fine emulsor screen. Droplet size development is tracked by laser diffraction according to ISO 13320:2020, with the span metric held below 1.5 after solvent removal. When impeller tip speed is allowed to fall below 8 m/s, batch-to-batch particle size drift exceeds 10% relative standard deviation and the 90th percentile of the volume distribution shifts above 125 µm. Hardening is carried out by stirring at 300 rpm for 4 h at 25 °C, followed by vacuum stripping at 25 °C for 8 h; residual dichloromethane is tested against the 600 ppm limit specified in ICH Q3C. Drug loading is maintained between 5% w/w and 20% w/w. Above 20% w/w, differential scanning calorimetry at a heating rate of 10 K/min under nitrogen often resolves an endotherm corresponding to free peptide salt, indicating phase separation rather than molecular dispersion. The amorphous polyester matrix suppresses crystallinity-driven expulsion; however, encapsulation efficiency declines if the inner aqueous phase exceeds 10% v/v of the oil phase due to droplet coalescence during the initial emulsification window.

What Restricts Burst Release in Amorphous PDLLA Coatings on Resorbable Stent Platforms?

Spray-coated drug-eluting layers based on R 207 S are processed from acetone-ethyl acetate blends with a drug-to-polymer ratio between 1:3 and 1:10. The solution is filtered through a 0.22 µm polytetrafluoroethylene membrane before delivery to an ultrasonic nozzle operating at 60 kHz. Coating thickness is controlled by liquid feed rate, sheath gas mass flow ratio, and number of passes; a target dry thickness of 2 µm to 5 µm is confirmed by scanning electron microscopy against a metallurgical reference standard. In-process monitoring uses near-infrared spectroscopy calibrated to residual acetone below 5,000 ppm, because retained solvent acts as a plasticizer and accelerates the initial drug release rate. The amorphous nature of R 207 S avoids crystallite boundaries that create microchannels for rapid moisture ingress. However, when the drug-to-polymer ratio exceeds 1:3, surface roughness increases beyond an average roughness of 0.4 µm under ISO 4287:1997, and adhesion loss is observed at the coating-substrate interface during mandrel bend tests. Hemocompatibility evaluation follows ISO 10993-4:2017 with complementary platelet adhesion imaging after citrated whole blood exposure for 60 min. The clinical device design file references ISO 25539-2:2020 for stent system testing; polymer-only degradation profiling is conducted according to ASTM F1635-16 in phosphate-buffered saline at 37 °C with pH maintained at 7.4.

For absorbable implant stock, the pre-drying step gates all downstream thermal processing. R 207 S is dried in a vacuum oven at 45 °C for 24 h to a moisture content below 500 ppm. A nitrogen purge of at least 2 L/min is maintained through the hopper; exposure to ambient air above 60% RH for more than 30 min is sufficient to raise the moisture level above 0.1% w/w and produce hydrolysis-induced melt viscosity loss. The material is fed into a co-rotating twin-screw extruder with a screw diameter of 16 mm and an L/D ratio of 25:1. Zone temperatures are programmed from 140 °C at the feed throat to 170 °C at the die, with screw speed maintained at 150 rpm and melt temperature measured by an infrared probe not exceeding 180 °C. At melt temperatures above 180 °C, torque decreases by more than 15% within 10 min and the pressure drop across the filter pack falls, indicating chain scission and a shift toward oligomeric species. The melt is extruded through a single-strand die and pelletized under dry air; pellets are then dried again before secondary processing. Viscosity stability is confirmed by dilute-solution viscometry according to ISO 1628-1:2021, with loss of inherent viscosity limited to 0.1 dL/g versus the certificate of analysis value of 1.7 dL/g measured at 0.1% in chloroform at 25 °C. For injection molding of small absorbable pins, a clamp force of 40 tons is applied in a mold with cold-runner temperature maintained below 25 °C, because the amorphous resin exhibits a narrow processing window between softening point and degradation onset. When barrel residence time exceeds 5 min at 170 °C, molded parts develop a yellowish tint and notched impact strength drops, although the material does not generate crystalline spherulites.

When Molecular Weight Defines Compression Molding Cycle Limits for Amorphous PLDL

Compression molding of amorphous poly(D,L-lactide) requires a narrow platen temperature band because the polymer has no crystalline lamellae to retain shape once viscosity drops. The resin is dried to 0.05% w/w moisture and then pressed between aluminum plates coated with a polytetrafluoroethylene release film. Press force is ramped from 2 metric tons to 15 metric tons over 3 min and held at 160 °C for 5 min. Cavity-edge thermocouples record a lag of 8 °C to 12 °C from set point during the first cycle; below 145 °C, edge-flow defects appear as radial striations in a 0.5 mm plaque. Demolding is performed only after platen temperature has returned to 40 °C, because premature ejection at higher temperatures causes part deformation and surface adhesion to the release film. Tensile specimens are punched according to ISO 527-2:2012 type 5A geometry, and tensile modulus is recorded at a crosshead speed of 1 mm/min. For thin barrier films, the resulting plaques are further stabilized at 25 °C and 50% RH for 48 h before ASTM D638-14 testing; dimensional change during stabilization is less than 0.3% in the long axis. Published comparative data for this specific amorphous grade in compression-molded form is limited when compared with injection-molded semicrystalline poly(L-lactide); process limits are therefore verified with a differential scanning calorimetry scan to confirm the absence of a melting endotherm and with ISO 1133-1:2022 melt mass-flow rate checks before production lots are released.

Electrospun Barrier Mesh Construction and Degradation-Dependent Porosity

Electrospinning of R 207 S from 1,1,1,3,3,3-hexafluoroisopropanol at 10% w/v produces fiber mats with fiber diameter distributions controlled by tip-to-collector distance, applied voltage, and solution feed rate. When the collector gap is fixed at 15 cm and the voltage is set to 18 kV, the mean fiber diameter falls near 1.2 µm; increasing the voltage to 25 kV at the same gap broadens the distribution and shifts the lower quartile to 0.8 µm. Residual solvent is removed in a vacuum chamber at 0.1 mbar for 12 h, and mesh thickness is measured according to ISO 5084:1996 using a pressure foot area of 200 mm². Tensile properties are assessed on rectangular specimens cut with a fresh razor blade and tested in a universal testing machine equipped with a 50 N load cell; crosshead speed is 5 mm/min. The resulting nonwoven structure displays strain-hardening at large deformation because fibers align along the tensile axis, but strain at break remains below 50% after 7 d of immersion in phosphate-buffered saline at 37 °C, indicating hydrolytic chain scission precedes full mass loss. Biological evaluation of the mesh follows ISO 10993-5:2009 and ISO 10993-10:2021. For implantation use, a supplementary subchronic implantation study under ISO 10993-6:2016 is required if the mesh is intended to remain in tissue beyond 12 weeks, because the amorphous matrix loses mechanical integrity before complete resorption.

Solvent exchange rate governs initial burst in high-lactide amorphous depots

N-methyl-2-pyrrolidone solvent exchange for injectable depot formation relies on the miscibility gap between the solvent and phosphate-buffered saline. R 207 S is dissolved at 30% w/w in N-methyl-2-pyrrolidone and extruded through a 21 G needle into a gelation bath maintained at 37 °C. The outer region undergoes phase inversion within 3 min to 5 min, while the core remains solvent-rich for up to 24 h, creating a dense skin over a macroporous interior. In vitro release is measured in 0.01 M phosphate-buffered saline at 37 °C and 60 rpm using USP apparatus 2, with an initial 24 h elution of 15% to 25% of a low-molecular-weight marker, followed by a degradation-controlled phase after 14 d. Where direct comparison to semicrystalline poly(L-lactide) depot systems is required, published data for this specific formulation configuration is limited; the design range is therefore verified through a benchtop gelation screen rather than an assumed release model. Residual solvent in the formed depot is quantified by headspace gas chromatography, with the N-methyl-2-pyrrolidone release limit set according to ICH Q3C for parenteral products. The absence of crystalline phase in R 207 S eliminates the need for pre-melting, but the polymer solution must be sterilized by filtration through a 0.22 µm polyethersulfone membrane before aseptic filling; terminal gamma irradiation above 25 kGy is documented to reduce inherent viscosity by more than 10%, so the formulation is not recommended for high-dose irradiation finishing unless a chain-scission allowance is incorporated into the release specification.